Histopathological and Molecular Characteristics of Pediatric Adrenocortical Tumors: where Do we Stand?
Open Access
- 19 February 2026
- journal article
- review article
- Published by Springer Nature in Endocrine Pathology
- Vol. 37 (1) , 9
Abstract
Pediatric adrenal cortical carcinoma (ACC) is a rare heterogeneous cancer type that is incompletely understood and differs from its adult counterpart in clinical presentation, histopathological characteristics, genomic landscape, and prognosis. Pediatric ACC has a bimodal age distribution for children with ACC, with the highest incidence in young children and adolescents. Tumors commonly present with an endocrine syndrome such as virilization or Cushing’s syndrome, associated with hormone overproduction. Surgical resection is the primary treatment. Adjuvant therapies such as mitotane or chemotherapy can lead to (severe) side effects in children and should be closely monitored. Histopathological assessment commonly relies on the AFIP/Wieneke classification, with the modified reticulin algorithm also providing predictive value. Recently, the two-step scoring system by Picard aimed to integrate the AFIP/Wieneke classification and the Children’s Oncology Group (COG) staging system into a two-step model. Molecularly, pediatric ACC is strongly associated with germline variants of TP53 and loss of heterozygosity of chromosomes 11 and 17. Somatic variants in several genes, including ATRX and CTNNB1, have been identified and are associated with poor prognosis. Multiple factors, such as age, tumor size, and biomarkers, with Ki67-labeling index being most important, are of prognostic value. Despite research advances, overall survival remains poor and worsens with older age at diagnosis and advanced disease. To improve survival rates of pediatric ACC further research is necessary aiming at optimizing therapeutic strategies in these patients. This review summarizes current knowledge of this challenging tumor and highlights recent advances in the field.Keywords
This publication has 92 references indexed in Scilit:
- TP53 p.Arg337His geographic distribution correlates with adrenocortical tumor occurrenceMolecular Genetics & Genomic Medicine, 2020
- The who, when, and why of primary adrenal malignancies: Insights into the epidemiology of a rare clinical entityCancer, 2018
- Nutlin‐3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutationCancer Medicine, 2018
- Contribution of the TP53 R337H mutation to the cancer burden in southern Brazil: Insights from the study of 55 families of children with adrenocortical tumorsCancer, 2017
- Low expression of HLA‐DRA, HLA‐DPA1, and HLA‐DPB1 is associated with poor prognosis in pediatric adrenocortical tumors (ACT)Pediatric Blood & Cancer, 2014
- Spindle assembly checkpoint gene expression in childhood adrenocortical tumors (ACT): Overexpression of Aurora kinases A and B is associated with a poor prognosisPediatric Blood & Cancer, 2013
- Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumorsGenes, Chromosomes and Cancer, 2012
- Detailed haplotype analysis at theTP53locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effectHuman Mutation, 2009
- Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinomaCancer, 2009
- Adrenocortical carcinomaCancer, 2000